GSK exec: Pharma ills require more M&A

The pharmaceutical industry faces a stark environment of rising costs and stagnant drug innovation that will ensure more acquisitions are done, as drugmakers try to offset painful and growing business pressures, GlaxoSmithKline's chief strategy officer said. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.